| Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ... New England Journal of Medicine 370 (22), 2071-2082, 2014 | 4470 | 2014 |
| Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group … C Comarmond, C Pagnoux, M Khellaf, JF Cordier, M Hamidou, JF Viallard, ... Arthritis & Rheumatism 65 (1), 270-281, 2013 | 899 | 2013 |
| Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised … AU Wells, KR Flaherty, KK Brown, Y Inoue, A Devaraj, L Richeldi, T Moua, ... The lancet Respiratory medicine 8 (5), 453-460, 2020 | 452 | 2020 |
| Comparison of long-term outcome between anti-Jo1-and anti-PL7/PL12 positive patients with antisynthetase syndrome I Marie, S Josse, O Decaux, S Dominique, E Diot, C Landron, P Roblot, ... Autoimmunity reviews 11 (10), 739-745, 2012 | 221 | 2012 |
| Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients P Fillatre, O Decaux, S Jouneau, M Revest, A Gacouin, ... The American journal of medicine 127 (12), 1242. e11-1242. e17, 2014 | 208 | 2014 |
| Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS M Grégoire, F Uhel, M Lesouhaitier, A Gacouin, M Guirriec, F Mourcin, ... European Respiratory Journal 52 (2), 2018 | 167 | 2018 |
| Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis R Borie, L Tabèze, G Thabut, H Nunes, V Cottin, S Marchand-Adam, ... European Respiratory Journal 48 (6), 1721-1731, 2016 | 161 | 2016 |
| Women and COPD: do we need more evidence? C Gut-Gobert, A Cavaillès, A Dixmier, S Guillot, S Jouneau, C Leroyer, ... European Respiratory Review 28 (151), 2019 | 138 | 2019 |
| Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study F Robert-Gangneux, S Belaz, M Revest, P Tattevin, S Jouneau, O Decaux, ... Journal of clinical microbiology 52 (9), 3370-3376, 2014 | 136 | 2014 |
| Chest CT in COVID-19 pneumonia: A review of current knowledge C Jalaber, T Lapotre, T Morcet-Delattre, F Ribet, S Jouneau, M Lederlin Diagnostic and interventional Imaging 101 (7-8), 431-437, 2020 | 131 | 2020 |
| The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study A Tazi, C de Margerie, JM Naccache, S Fry, S Dominique, S Jouneau, ... Orphanet Journal of rare diseases 10, 1-10, 2015 | 122 | 2015 |
| Severe hematologic complications after lung transplantation in patients with telomerase complex mutations R Borie, C Kannengiesser, S Hirschi, J Le Pavec, H Mal, E Bergot, ... The Journal of Heart and Lung Transplantation 34 (4), 538-546, 2015 | 118 | 2015 |
| Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study CH Marquette, J Boutros, J Benzaquen, M Ferreira, J Pastre, C Pison, ... The Lancet Respiratory Medicine 8 (7), 709-716, 2020 | 115 | 2020 |
| Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease A Lescoat, M Lelong, M Jeljeli, C Piquet-Pellorce, C Morzadec, A Ballerie, ... Biochemical pharmacology 178, 114103, 2020 | 114 | 2020 |
| Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence L Richeldi, F Varone, M Bergna, J de Andrade, J Falk, R Hallowell, ... European Respiratory Review 27 (150), 2018 | 108 | 2018 |
| Inflammatory biomarkers in airways of patients with severe asthma compared with non‐severe asthma P Macedo, M Hew, A Torrego, S Jouneau, T Oates, A Durham, KF Chung Clinical & Experimental Allergy 39 (11), 1668-1676, 2009 | 101 | 2009 |
| Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries TM Maher, M Molina-Molina, AM Russell, F Bonella, S Jouneau, ... BMC pulmonary medicine 17, 1-12, 2017 | 99 | 2017 |
| Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase K Simonin-Le Jeune, A Le Jeune, S Jouneau, C Belleguic, PF Roux, ... PloS one 8 (9), e75667, 2013 | 94 | 2013 |
| Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis G Lorillon, A Bergeron, L Detourmignies, S Jouneau, B Wallaert, J Frija, ... American Journal of Respiratory and Critical Care Medicine 186 (9), 930-932, 2012 | 91 | 2012 |
| Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis L Richeldi, M Kolb, S Jouneau, WA Wuyts, B Schinzel, S Stowasser, ... BMC Pulmonary Medicine 20, 1-8, 2020 | 89 | 2020 |
Bruno Crestaniuniversité paris diderot在 bch.aphp.fr 的电子邮件经过验证
